RNAi-mediated gene silencing in non-human primates

A Receptor-Mediated Pathway for Cholesterol Homeostasis

Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703 · see citing works

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938 · see citing works

C-Reactive Protein Levels and Outcomes after Statin Therapy

Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292 · see citing works

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,189 · see citing works

Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250 · see citing works

Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7

Hornung, V., Guenthner‐Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A. M., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,233 · see citing works

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168 · see citing works

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,022 · see citing works

The RNAi revolution

Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 730 · see citing works

Inhibition of respiratory viruses by nasally administered siRNA

Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2004) · Nature Medicine · doi:10.1038/nm1164 · Cited by 725 · see citing works

Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging

Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 593 · see citing works

Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors: Similarities and Differences

Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527 · see citing works

A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

Levin, A. A. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00140-2 · Cited by 438 · see citing works

An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection

Palliser, D., Chowdhury, D., Wang, Q.-Y., Lee, S. J., Bronson, R. T., Knipe, D. M., & Lieberman, J. (2006) · Nature · doi:10.1038/nature04263 · Cited by 410 · see citing works

The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes

Chonn, A., Cullis, P. R., & Devine, D. V. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.12.4234 · Cited by 367 · see citing works

Similarities and Differences

Diamond, G., Beckloff, N., Ryan, L. K., Res, J. D., Diamond, G., Beckloff, N., & Ryan, L. K. (2005) · SAGE Publications Ltd eBooks · doi:10.4135/9781849208765.n5 · Cited by 339 · see citing works

Sustained Small Interfering RNA-Mediated HumanImmunodeficiency Virus Type 1 Inhibition in PrimaryMacrophages

Song, E., Lee, S., Dykxhoorn, D. M., Novina, C. D., Zhang, D., Crawford, K. D., Černý, J., Sharp, P. A., Lieberman, J., Manjunath, N., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7174-7181.2003 · Cited by 230 · see citing works

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., & Perera, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400492-jlr200 · Cited by 224 · see citing works

Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference

Thakker, D. R., Natt, F., Hüsken, D., Maier, R., Müller, M., van der Putten, H., Hoyer, D., & Cryan, J. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406214101 · Cited by 211 · see citing works

The Prospect of Silencing Disease Using RNA Interference

Shankar, P. (2005) · JAMA · doi:10.1001/jama.293.11.1367 · Cited by 140 · see citing works

Liposomal drug delivery systems: From concept to clinical applications

Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · see citing works

Non-viral vectors for gene-based therapy

Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · see citing works

Knocking down barriers: advances in siRNA delivery

Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · see citing works

Advances in oligonucleotide drug delivery

Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,026 · see citing works

Rational design of cationic lipids for siRNA delivery

Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · see citing works

Delivery materials for siRNA therapeutics

Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800 · see citing works

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636 · see citing works

Therapeutic siRNA: state of the art

Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586 · see citing works

Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications

Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399 · see citing works

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

Bennett, C. F., & Swayze, E. E. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,381 · see citing works

The current landscape of nucleic acid therapeutics

Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371 · see citing works

Drug delivery systems for RNA therapeutics

Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349 · see citing works

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo

Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267 · see citing works

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms

Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261 · see citing works

Nanomaterials for Theranostics: Recent Advances and Future Challenges

Lim, E., Kim, T., Paik, S., Haam, S., Huh, Y., & Lee, K. (2014) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,236 · see citing works

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

Akinc, A., Zumbuehl, A., Goldberg, M. S., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S., Nguyen, D. N., Fuller, J. E., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,228 · see citing works

The promises and pitfalls of RNA-interference-based therapeutics

Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,219 · see citing works

Interfering with disease: a progress report on siRNA-based therapeutics

de Fougerolles, A., Vornlocher, H., Maraganore, J. M., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,202 · see citing works

Lipid Nanoparticle Systems for Enabling Gene Therapies

Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208 · see citing works

Overcoming cellular barriers for RNA therapeutics

Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139 · see citing works

Transvascular delivery of small interfering RNA to the central nervous system

Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246 · see citing works

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application

Jackson, A. L., & Linsley, P. S. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,092 · see citing works

RNAi therapeutics: a potential new class of pharmaceutical drugs

Bumcrot, D. A., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,086 · see citing works

Strategies for silencing human disease using RNA interference

Kim, D. H., & Rossi, J. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2006 · Cited by 1,078 · see citing works

Illuminating the silence: understanding the structure and function of small RNAs

Rana, T. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2085 · Cited by 837 · see citing works

Therapeutic targeting of microRNAs: current status and future challenges

Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,028 · see citing works

The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities

Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., D’Urso, L., Pagliuca, A., Biffoni, M., Labbaye, C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1880 · Cited by 989 · see citing works

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971 · see citing works

Lipid-like materials for low-dose, in vivo gene silencing

Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969 · see citing works

RNAi therapeutics: Principles, prospects and challenges

Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895 · see citing works

Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy

Famulok, M., Hartig, J. S., & Mayer, G. (2007) · Chemical Reviews · doi:10.1021/cr0306743 · Cited by 889 · see citing works

Chemistry, structure and function of approved oligonucleotide therapeutics

Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 864 · see citing works

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

Bartlett, D. W., Su, H. C., Hildebrandt, I. J., Weber, W., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 808 · see citing works

Knocking down disease: a progress report on siRNA therapeutics

Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 810 · see citing works

Delivery of siRNA Therapeutics: Barriers and Carriers

Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L. ‐. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 804 · see citing works

Progress in developing cationic vectors for non-viral systemic gene therapy against cancer

Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A., & Benoît, J. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.04.036 · Cited by 769 · see citing works

Current prospects for RNA interference-based therapies

Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 760 · see citing works

Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine

Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P., & Lee, S. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.005 · Cited by 731 · see citing works

Nanodelivery of nucleic acids

Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719 · see citing works

GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics

Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711 · see citing works

Supramolecular self-assemblies as functional nanomaterials

Busseron, E., Ruff, Y., Moulin, É., & Giuseppone, N. (2013) · Nanoscale · doi:10.1039/c3nr02176a · Cited by 699 · see citing works

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Tabernero, J. M., Shapiro, G. I., LoRusso, P. M., Cervantes, A. M. R., Schwartz, G. K., Weiss, G. J., Paz-Ares, L. G., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 700 · see citing works

In vivo imaging of siRNA delivery and silencing in tumors

Medarova, Z., Pham, W., Farrar, C., Petkova, V., & Moore, A. (2007) · Nature Medicine · doi:10.1038/nm1486 · Cited by 697 · see citing works

The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery

Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703 · see citing works

Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown

Wittrup, A., Ai, A., Liu, X., Hamar, P., Trifonova, R., Charisse, K., Manoharan, M., Kirchhausen, T., & Lieberman, J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3298 · Cited by 693 · see citing works

Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.28 · Cited by 685 · see citing works

Progress towards in Vivo Use of siRNAs

Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677 · see citing works

siRNA vs. shRNA: Similarities and differences

Rao, D. D., Vorhies, J. S., Senzer, N. N., & Nemunaitis, J. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 658 · see citing works

Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes

Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658 · see citing works

siRNA delivery systems for cancer treatment

Oh, Y., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 641 · see citing works

Lipid-based Nanoparticles for Nucleic Acid Delivery

Li, W., & Szoka, F. C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9180-5 · Cited by 642 · see citing works

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 635 · see citing works

Breaking down the barriers: siRNA delivery and endosome escape

Domińska, M., & Dykxhoorn, D. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.066399 · Cited by 632 · see citing works

Lipids and Lipid Derivatives for RNA Delivery

Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 638 · see citing works

Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone

Sato, Y., Murase, K., Kato, J., Kobune, M., Sato, T., Kawano, Y., Takimoto, R., Takada, K., Miyanishi, K., Matsunaga, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1396 · Cited by 610 · see citing works

The importance of nanoparticle shape in cancer drug delivery

Truong, N. P., Whittaker, M. R., Mak, C. W., & Davis, T. P. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.950564 · Cited by 594 · see citing works

Lipid nanoparticles for nucleic acid delivery: Current perspectives

Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 593 · see citing works

Lipid nanoparticles enabling gene therapies: from concepts to clinical utility

Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592 · see citing works

Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation

Aouadi, M., Tesz, G. J., Nicoloro, S. M. C., Wang, M., Chouinard, M., Soto, E. R., Ostroff, G. R., & Czech, M. (2009) · Nature · doi:10.1038/nature07774 · Cited by 572 · see citing works

CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery

Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560 · see citing works

The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation

Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.027 · Cited by 546 · see citing works

microRNAs and the immune response

Lindsay, M. A. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.04.004 · Cited by 532 · see citing works

Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins

Huang, H., Sun, F., Owen, D. M., Li, W., Chen, Y., Gale, M., & Ye, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700760104 · Cited by 533 · see citing works

Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics

Kulkarni, J. A., Witzigmann, D., Chen, S., Cullis, P. R., & van der Meel, R. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00368 · Cited by 534 · see citing works

Human laminopathies: nuclei gone genetically awry

Capell, B. C., & Collins, F. S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1906 · Cited by 515 · see citing works

The 60-year evolution of lipid nanoparticles for nucleic acid delivery

Cullis, P. R., & Felgner, P. L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00977-6 · Cited by 517 · see citing works

Self-assembled mRNA vaccines

Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514 · see citing works

Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles

Mui, B. L., Tam, Y. K., Jayaraman, M., Ansell, S. M., Du, X., Tam, Y. Y. C., Lin, P. J. C., Chen, S., Narayanannair, J. K., Rajeev, K. G., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.66 · Cited by 509 · see citing works

Molecular Mechanisms and Biological Functions of siRNA

Dana, H., Chalbatani, G. M., Mahmoodzadeh, H., Gharagouzloo, E., Karimloo, R., Rezaiean, O., Moradzadeh, A., Mazraeh, A., Marmari, V., Rashno, M. M., et al. (2017) · International Journal of Biomedical Science · doi:10.59566/ijbs.2017.13048 · Cited by 507 · see citing works

Targeting kidney mesangium by nanoparticles of defined size

Choi, C. H. J., Zuckerman, J. E., Webster, P. C., & Davis, M. E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103573108 · Cited by 503 · see citing works

Nonviral delivery of synthetic siRNAs in vivo

Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464 · see citing works

Lipid-based systemic delivery of siRNA

Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463 · see citing works

Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion

Gastaminza, P., Cheng, G., Wieland, S. F., Zhong, J., Liao, W., & Chisari, F. V. (2007) · Journal of Virology · doi:10.1128/jvi.02053-07 · Cited by 463 · see citing works

A Comprehensive Review of mRNA Vaccines

Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457 · see citing works

Preclinical and clinical development of siRNA-based therapeutics

Özcan, G., Özpolat, B., Coleman, R. L., Sood, A. K., & Lopez‐Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 451 · see citing works

Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease

Adams, D., Koike, H., Slama, M., & Coelho, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0210-4 · Cited by 450 · see citing works

Liposomal siRNA nanocarriers for cancer therapy

Özpolat, B., Sood, A. K., & Lopez‐Berestein, G. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.008 · Cited by 445 · see citing works

Microfluidic formulation of nanoparticles for biomedical applications

Shepherd, S. J., Issadore, D., & Mitchell, M. J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120826 · Cited by 448 · see citing works

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

DeVincenzo, J. P., Lambkin‐Williams, R., Wilkinson, T. M. A., Cehelsky, J. E., Nochur, S., Walsh, E. E., Meyers, R. E., Gollob, J., & Vaishnaw, A. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912186107 · Cited by 440 · see citing works

Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA

Woodrow, K. A., Cu, Y., Booth, C. J., Saucier-Sawyer, J. K., Wood, M. J., & Saltzman, W. M. (2009) · Nature Materials · doi:10.1038/nmat2444 · Cited by 437 · see citing works

New Generation of Multifunctional Nanoparticles for Cancer Imaging and Therapy

Park, K., Lee, S., Kang, E., Kim, K., Choi, K., & Kwon, I. C. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200801655 · Cited by 430 · see citing works

Chemically modified siRNA: tools and applications

Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431 · see citing works

Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides

Juliano, R. L., Alam, M. R., Dixit, V., & Kang, H. M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 430 · see citing works

Pharmacology of Antisense Drugs

Bennett, C. F., Baker, B. F., Pham, N. C., Swayze, E. E., & Geary, R. S. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 429 · see citing works

Cationic lipids and polymers mediated vectors for delivery of siRNA

Zhang, S., Zhao, B., Jiang, H., Wang, B., & Ma, B. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.07.016 · Cited by 421 · see citing works

Perspectives and opportunities for nanomedicine in the management of atherosclerosis

Lobatto, M. E., Fuster, V., Fayad, Z. A., & Mulder, W. J. M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3578 · Cited by 423 · see citing works

Principles and effects of microRNA-mediated post-transcriptional gene regulation

Engels, B., & Hutvágner, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209909 · Cited by 410 · see citing works

Cytokines as biomarkers of nanoparticle immunotoxicity

Elsabahy, M., & Wooley, K. L. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60064e · Cited by 408 · see citing works

Development of a novel endosomolytic diblock copolymer for siRNA delivery

Convertine, A. J., Benoit, D. S. W., Duvall, C. L., Hoffman, A. S., & Stayton, P. S. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.10.004 · Cited by 407 · see citing works

Simultaneous Delivery of siRNA and Paclitaxel via a “Two-in-One” Micelleplex Promotes Synergistic Tumor Suppression

Sun, T., Du, J., Yao, Y., Mao, C., Dou, S., Huang, S., Zhang, P., Leong, K. W., Song, E., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406 · see citing works

Materials for non-viral intracellular delivery of messenger RNA therapeutics

Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.032 · Cited by 400 · see citing works

MicroRNAs in Disease and Potential Therapeutic Applications

Soifer, H. S., Rossi, J. J., & Sætrom, P. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300311 · Cited by 395 · see citing works

Gene therapy progress and prospects: non-viral gene therapy by systemic delivery

Li, S.-D., & Huang, L. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302838 · Cited by 392 · see citing works

Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles

Schlich, M., Palomba, R., Costabile, G., Mizrahy, S., Pannuzzo, M., Peer, D., & Decuzzi, P. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10213 · Cited by 387 · see citing works

Liposomal Delivery Systems: Design Optimization and Current Applications

Lila, A. S. A., & Ishida, T. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00624 · Cited by 386 · see citing works

Shedding Light on Extracellular Vesicle Biogenesis and Bioengineering

Teng, F., & Fussenegger, M. (2020) · Advanced Science · doi:10.1002/advs.202003505 · Cited by 384 · see citing works

Lipid nanoparticle technology for therapeutic gene regulation in the liver

Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376 · see citing works

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA

Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382 · see citing works

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

Kortylewski, M., Swiderski, P. M., Herrmann, A., Wang, L., Kowolik, C. M., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1564 · Cited by 378 · see citing works

Recent advances in siRNA delivery mediated by lipid-based nanoparticles

Yonezawa, S., Koide, H., & Asai, T. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.022 · Cited by 386 · see citing works

A loss-of-function RNA interference screen for molecular targets in cancer

Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H. G., Lenz, G., Lam, L. T., Davé, S. S., Yang, L., Powell, J. I., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 606 · see citing works

Divining cancer cell weaknesses

Kaelin, W. G. (2006) · Nature · doi:10.1038/441032a · Cited by 6 · see citing works

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,189 · see citing works

RNAI ADVANCE

Arnaud, C. H. (2006) · Chemical & Engineering News · doi:10.1021/cen-v084n014.p012a

Breakthrough for systemic RNAi

Whalley, K. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2041 · Cited by 2 · see citing works